Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Diebold, Kendall [1 ]
Worth, Sarah [2 ]
Bachiashvili, Kimo [2 ]
Vachhani, Pankit [3 ]
Rangaraju, Sravanti [1 ]
Espinoza-Gutarra, Manuel [1 ]
Al-Kadhimi, Zaid [1 ]
Bhatia, Ravi [1 ]
Jamy, Omer [4 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[3] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Div Hematol Oncol, Birmingham, AL USA
[4] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185198
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
    Knight, Tristan E.
    Edwards, Holly
    Meshinchi, Soheil
    Taub, Jeffrey W.
    Ge, Yubin
    CANCERS, 2022, 14 (14)
  • [32] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Maiti, Abhishek
    DiNardo, Courtney D.
    Daver, Naval G.
    Rausch, Caitlin R.
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Borthakur, Gautam
    Bose, Prithviraj
    Issa, Ghayas C.
    Short, Nicholas J.
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Jain, Nitin
    Ohanian, Maro
    Takahashi, Koichi
    Thompson, Philip A.
    Loghavi, Sanam
    Montalbano, Kathryn S.
    Pierce, Sherry
    Wierda, William G.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [33] Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia
    Borek, Weronika E.
    Nobre, Luis
    Pedicona, S. Federico
    Campbell, Amy E.
    Christopher, Josie A.
    Nawaz, Nazrath
    Perkins, David N.
    Moreno-Cardoso, Pedro
    Kelsall, Janet
    Ferguson, Harriet R.
    Patel, Bela
    Gallipoli, Paolo
    Arruda, Andrea
    Ambinder, Alex J.
    Thompson, Andrew
    Williamson, Andrew
    Ghiaur, Gabriel
    Minden, Mark D.
    Gribben, John G.
    Britton, David J.
    Cutillas, Pedro R.
    Dokal, Arran D.
    EBIOMEDICINE, 2024, 108
  • [34] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary
    Bradley, Terrence
    Tiu, Ramon, V
    Naqvi, Kiran
    Dail, Monique
    Brackman, Deanna
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
  • [35] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Abhishek Maiti
    Courtney D. DiNardo
    Naval G. Daver
    Caitlin R. Rausch
    Farhad Ravandi
    Tapan M. Kadia
    Naveen Pemmaraju
    Gautam Borthakur
    Prithviraj Bose
    Ghayas C. Issa
    Nicholas J. Short
    Musa Yilmaz
    Guillermo Montalban-Bravo
    Alessandra Ferrajoli
    Elias J. Jabbour
    Nitin Jain
    Maro Ohanian
    Koichi Takahashi
    Philip A. Thompson
    Sanam Loghavi
    Kathryn S. Montalbano
    Sherry Pierce
    William G. Wierda
    Hagop M. Kantarjian
    Marina Y. Konopleva
    Blood Cancer Journal, 11
  • [36] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [37] BURDEN OF ILLNESS OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED STATES
    Sotak, M.
    Marin, M.
    Coombs, J.
    Schiller, G.
    Teitelbaum, A.
    HAEMATOLOGICA, 2012, 97 : 35 - 35
  • [38] FLT3-mutated acute myeloid leukaemia: a new opportunity
    Przespolewski, Amanda C.
    Griffiths, Elizabeth
    LANCET, 2023, 401 (10388): : 1546 - 1548
  • [39] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
    Perl, Alexander E.
    Hosono, Naoko
    Montesinos, Pau
    Podoltsev, Nikolai
    Martinelli, Giovanni
    Panoskaltsis, Nicki
    Recher, Christian
    Smith, Catherine C.
    Levis, Mark J.
    Strickland, Stephen
    Rollig, Christoph
    Gross-Langenhoff, Marco
    Chou, Wen-Chien
    Lee, Je-Hwan
    Yokoyama, Hisayuki
    Hasabou, Nahla
    Lu, Qiaoyang
    Tiu, Ramon, V
    Altman, Jessica K.
    BLOOD CANCER JOURNAL, 2022, 12 (05)
  • [40] Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
    Ma, Jun
    Zhao, Shoujing
    Qiao, Xinan
    Knight, Tristan
    Edwards, Holly
    Polin, Lisa
    Kushner, Juiwanna
    Dzinic, Sijana H.
    White, Kathryn
    Wang, Guan
    Zhao, Lijing
    Lin, Hai
    Wang, Yue
    Taub, Jeffrey W.
    Ge, Yubin
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6815 - 6826
12345